Medpage Today on MSN19h
Adding HIPEC Boosts Survival in Recurrent Ovarian CancerThe 5-year OS rates were 46% in the HIPEC group versus 38% in the no-HIPEC group, they noted in Lancet Oncology. The trial ...
Researchers from the Walter and Eliza Hall Institute (WEHI)in Australia have found a new way to predict a subset of patients ...
Researchers found significant differences in ovarian cancer survival among Asian American subgroups, emphasizing the ...
Nuvectis Pharma shares fell steeply after updated data from its early-stage study evaluating NXP800 to treat an aggressive type of ovarian cancer showed that a change in the dosing schedule only ...
University of Iowa researchers have landed a $10-million federal grant to develop a new treatment for ovarian cancer. Jill ...
A University of Iowa researcher is using federal funding to develop a new approach to combat ovarian cancer. According to the ...
A simple blood test could soon predict which ovarian cancer patients will stop responding to their treatment, paving the way ...
Data presented as part of a poster at the SITC 2024 ConferenceSOUTH SAN FRANCISCO, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics ...
Researchers at the University of California San Diego are hoping to drastically shorten the time between a cancer diagnosis ...
The Ovarian Cancer Research Alliance offers specialized services and support to help ovarian cancer patients find a community ...
CERo Therapeutics (CERO) announces the presentation of preclinical data demonstrating the capability of its lead compound CER-1236 to kill ...
The company has discontinued the Phase I/II trial of its only clinical candidate due to a potential “unfavourable ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback